Clinical Trials Browser

NCT03866382 2026-04-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

160 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06388720 2026-04-13

IMGeS

Phase 2 Recruiting

82 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07061964 2026-04-13

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Phase 2 Recruiting

111 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06567743 2026-04-08

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Phase 2 Recruiting

325 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06760819 2026-04-08

panSOHO

Phase 2 Recruiting

111 enrolled

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors

NCT06833073 2026-04-06

INTerpath-011

Phase 2 Recruiting

308 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07420517 2026-03-30

DutaBCa-1

Phase 2 Recruiting

95 enrolled

Genitourinary

Urinary Bladder Neoplasms, Recurrence

NCT07475403 2026-03-30

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Phase 2 Recruiting

53 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06503146 2026-03-27

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Phase 2 Recruiting

320 enrolled

CNSEndocrineGastrointestinalGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT07050771 2026-03-12

Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery

Phase 2 Recruiting

148 enrolled

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Kidney Neoplasms, Neoplasms, Ovarian Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

34 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06528990 2026-03-05

Telehealth Intervention for Ostomy Self-Management

Phase 2 Recruiting

150 enrolled

GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Colorectal Neoplasms

NCT05581589 2026-02-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Phase 2 Recruiting

18 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

Phase 2 Recruiting

25 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06630416 2026-02-24

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Phase 2 Recruiting

64 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT06290687 2026-02-18

Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy

Phase 2 Recruiting

40 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

740 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06733363 2026-01-27

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

344 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

Phase 2 Recruiting

20 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04879329 2026-01-07

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Phase 2 Recruiting

372 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07307456 2025-12-29

Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration

Phase 2 Recruiting

31 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07285044 2025-12-22

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Phase 2 Recruiting

27 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidMyeloidPlasma cellThoracic

Amyloidosis, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Lung Neoplasms, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Lymphoma, Mantle-Cell

NCT06263153 2025-12-17

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Phase 2 Recruiting

24 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07087860 2025-12-09

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT06091124 2025-12-08

NEOBLAST

Phase 2 Recruiting

22 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03915678 2025-10-06

AGADIR

Phase 2 Recruiting

247 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT06237920 2025-09-03

TURANDORELA

Phase 2 Recruiting

90 enrolled

Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06571708 2025-09-02